Why the study?
What is the cost-effectiveness of various pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation?
What is the cost-effectiveness of various pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation?
This review summarizes the cost-effectiveness of various stroke prevention strategies in atrial fibrillation to inform clinical and health policy recommendations.
No takes yet. Share an insight, caveat, or question.
Offers a consolidated view of AF stroke prophylaxis cost-effectiveness; leaves open direct clinical application pending updated analyses.
Solomon et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: